Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

Literature DB >> 6413638

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

E A Grimm, R J Robb, J A Roth, L M Neckers, L B Lachman, D J Wilson, S A Rosenberg.

Abstract

Purified interleukin 2 (IL-2) was found to be sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer (LAK) cells. The LAK activation factor was directly and consistently associated with IL-2 activity using classic protein purification techniques, adsorption to IL-2-dependent cell lines, and inhibition with anti-Tac antibody. As yet, no other cytokines have been found that perform the same role.

Entities: Gene

Mesh：

Substances：

Year: 1983 PMID： 6413638 PMCID： PMC2187385 DOI： 10.1084/jem.158.4.1356

Source DB: PubMed Journal: J Exp Med ISSN： 0022-1007 Impact factor: 14.307

13 in total

1. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors: T Uchiyama; S Broder; T A Waldmann
Journal: J Immunol Date: 1981-04 Impact factor: 5.422

2. Identification of T cell lymphoma tumor antigens on human T cell lines.

Authors: J Kaplan; J Tilton; W D Peterson
Journal: Am J Hematol Date: 1976 Impact factor: 10.047

3. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Authors: M T Lotze; E A Grimm; A Mazumder; J L Strausser; S A Rosenberg
Journal: Cancer Res Date: 1981-11 Impact factor: 12.701

4. The purification and properties of human T cell growth factor.

Authors: J W Mier; R C Gallo
Journal: J Immunol Date: 1982-03 Impact factor: 5.422

5. Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors: H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal: J Immunol Date: 1981-11 Impact factor: 5.422

6. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

Authors: I Yron; T A Wood; P J Spiess; S A Rosenberg
Journal: J Immunol Date: 1980-07 Impact factor: 5.422

7. Purification of human interleukin 1.

Authors: L B Lachman; S O Page; R S Metzgar
Journal: J Supramol Struct Date: 1980

8. In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity.

Authors: M T Lotze; S A Rosenberg
Journal: J Immunol Date: 1981-06 Impact factor: 5.422

9. Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line.

Authors: S Gillis; J Watson
Journal: J Exp Med Date: 1980-12-01 Impact factor: 14.307

10. T cell growth factor receptors. Quantitation, specificity, and biological relevance.

Authors: R J Robb; A Munck; K A Smith
Journal: J Exp Med Date: 1981-11-01 Impact factor: 14.307

73 in total

1. IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Authors: Emily Y Jen; Nancy J Poindexter; Elizabeth S Farnsworth; Elizabeth A Grimm
Journal: Melanoma Res Date: 2012-02 Impact factor: 3.599

2. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.

Authors: Maria de la Luz Garcia-Hernandez; Hiromasa Hamada; Joyce B Reome; Sara K Misra; Michael P Tighe; Richard W Dutton
Journal: J Immunol Date: 2010-03-17 Impact factor: 5.422

3. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

Authors: C J Honsik; G Jung; R A Reisfeld
Journal: Proc Natl Acad Sci U S A Date: 1986-10 Impact factor: 11.205

4. Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.

Authors: P McCulloch; G Gallagher; L P Walsh; Y Zaloom; J Xie
Journal: Clin Exp Immunol Date: 1991-09 Impact factor: 4.330

5. Phenotypic and functional characterization of T cells from patients with myasthenia gravis.

Authors: F Mokhtarian; M Pino; W Ofosu-Appiah; D Grob
Journal: J Clin Invest Date: 1990-12 Impact factor: 14.808

6. Activation of peripheral blood T cells via the p75 interleukin 2 receptor.

Authors: H Yagita; M Nakata; A Azuma; T Nitta; T Takeshita; K Sugamura; K Okumura
Journal: J Exp Med Date: 1989-10-01 Impact factor: 14.307

7. Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.

Authors: P Hersey; M MacDonald; S Schibeci; C Burns
Journal: Cancer Immunol Immunother Date: 1986 Impact factor: 6.968

8. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors: E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal: Cancer Immunol Immunother Date: 1988 Impact factor: 6.968

9. Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells.

Authors: M E Hemler; M B Brenner; J M McLean; J L Strominger
Journal: Proc Natl Acad Sci U S A Date: 1984-04 Impact factor: 11.205

10. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors: S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal: J Clin Immunol Date: 1993-05 Impact factor: 8.317